text_1: Alirocumab treatment reduces apo(a) fractional clearance rate.
text_2: Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandial plasma triglycerides or apoB48 concentrations.